These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26753892)

  • 1. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.
    Limsrivilai J; Charatcharoenwitthaya P; Pausawasdi N; Leelakusolvong S
    Am J Gastroenterol; 2016 Feb; 111(2):217-24. PubMed ID: 26753892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Tricyclics for Esophageal Hypersensitivity: Is it all Placebo Effect?
    Keefer L; Kahrilas PJ
    Am J Gastroenterol; 2016 Feb; 111(2):225-7. PubMed ID: 26882945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    Spechler SJ; Hunter JG; Jones KM; Lee R; Smith BR; Mashimo H; Sanchez VM; Dunbar KB; Pham TH; Murthy UK; Kim T; Jackson CS; Wallen JM; von Rosenvinge EC; Pearl JP; Laine L; Kim AW; Kaz AM; Tatum RP; Gellad ZF; Lagoo-Deenadayalan S; Rubenstein JH; Ghaferi AA; Lo WK; Fernando RS; Chan BS; Paski SC; Provenzale D; Castell DO; Lieberman D; Souza RF; Chey WD; Warren SR; Davis-Karim A; Melton SD; Genta RM; Serpi T; Biswas K; Huang GD
    N Engl J Med; 2019 Oct; 381(16):1513-1523. PubMed ID: 31618539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non-erosive reflux disease.
    Forcelini CM; Tomiozzo JC; Farré R; Van Oudenhove L; Callegari-Jacques SM; Ribeiro M; Madalosso BH; Fornari F
    Neurogastroenterol Motil; 2014 Feb; 26(2):187-95. PubMed ID: 24188252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial.
    Ostovaneh MR; Saeidi B; Hajifathalian K; Farrokhi-Khajeh-Pasha Y; Fotouhi A; Mirbagheri SS; Emami H; Barzin G; Mirbagheri SA
    Neurogastroenterol Motil; 2014 May; 26(5):670-8. PubMed ID: 24533896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
    Rodriguez-Stanley S; Zubaidi S; Proskin HM; Kralstein JR; Shetzline MA; Miner PB
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):442-50. PubMed ID: 16616348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.
    Rush DR; Stelmach WJ; Young TL; Kirchdoerfer LJ; Scott-Lennox J; Holverson HE; Sabesin SM; Nicholas TA
    J Fam Pract; 1995 Aug; 41(2):126-36. PubMed ID: 7636452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
    Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
    Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn.
    Martinucci I; de Bortoli N; Savarino E; Piaggi P; Bellini M; Antonelli A; Savarino V; Frazzoni M; Marchi S
    Neurogastroenterol Motil; 2014 Apr; 26(4):546-55. PubMed ID: 24433456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
    Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
    Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn.
    Frazzoni M; de Bortoli N; Frazzoni L; Furnari M; Martinucci I; Tolone S; Farioli A; Marchi S; Fuccio L; Savarino V; Savarino E
    J Gastroenterol; 2017 Apr; 52(4):444-451. PubMed ID: 27241210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial.
    Cheong PK; Ford AC; Cheung CKY; Ching JYL; Chan Y; Sung JJY; Chan FKL; Wu JCY
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):837-844. PubMed ID: 30361080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Ramelteon on Heartburn Symptoms of Patients With Gastroesophageal Reflux Disease and Chronic Insomnia: A Pilot Study.
    Jha LK; Fass R; Gadam R; Maradey-Romero C; Nasrollah L; Hershcovici T; Quan SF; Dickman R
    J Clin Gastroenterol; 2016 Feb; 50(2):e19-24. PubMed ID: 25887111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
    Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
    Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials.
    Johnson DA; Le Moigne A; Hugo V; Nagy P
    Curr Med Res Opin; 2015 Feb; 31(2):243-50. PubMed ID: 25478944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.